Low molecular weight heparin may prevent acute lung injury induced by sepsis in rats

Gene

Volumn 557, Issue 1, 2015, Pages 88-91

  Ning, Fangyu ^a,b   Wang, Xiaozhi ^b   Shang, Li ^c   Wang, Tao ^b   Lv, Changjun ^b   Qi, Zhijiang ^b   Wu, Dawei ^a  

^a SHANDONG UNIVERSITY   (China)

^b Department of Psychiatry Binzhou Medical University Affiliated Hospital   (China)

^c BINZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Low molecular weight heparin; Lung injury; Sepsis

Indexed keywords

CEFTRIAXONE; HIGH MOBILITY GROUP B1 PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1BETA; INTERLEUKIN 6; LOW MOLECULAR WEIGHT HEPARIN; MYELOPEROXIDASE; SODIUM CHLORIDE; TUMOR NECROSIS FACTOR ALPHA; ANTICOAGULANT AGENT; FIBRINOLYTIC AGENT; PEROXIDASE;

ACUTE LUNG INJURY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFECT; ENZYME IMMUNOASSAY; HISTOLOGY; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; INFLAMMATORY INFILTRATE; LUNG ALVEOLUS WALL; LUNG EDEMA; LUNG PARENCHYMA; LUNG SEQUESTRATION; MALE; NEUTROPHIL; NONHUMAN; PROTECTION; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RAT; SEPSIS; TISSUE WATER; ANIMAL; BIOSYNTHESIS; BLOOD; COMPLICATION; IMMUNOLOGY; LUNG; METABOLISM; PATHOLOGY; RANDOMIZATION; WISTAR RAT;

RATTUS;

ACUTE LUNG INJURY; ANIMALS; ANTICOAGULANTS; CEFTRIAXONE; FIBRINOLYTIC AGENTS; HEPARIN, LOW-MOLECULAR-WEIGHT; HMGB1 PROTEIN; INTERCELLULAR ADHESION MOLECULE-1; INTERLEUKIN-1BETA; INTERLEUKIN-6; LUNG; MALE; NEUTROPHILS; NF-KAPPA B; PEROXIDASE; RANDOM ALLOCATION; RATS; RATS, WISTAR; SEPSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84920182762     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2014.12.018     Document Type: Article

References (25)

1. Abraham E., Reinhart K., Opal S., Demeyer I., Doig C., Rodriguez A.L., Beale R., Svoboda P., Laterre P.F., Simon S., Light B., Spapen H., Stone J., Seibert A., Peckelsen C., De Deyne C., Postier R., Pettila V., Artigas A., Percell S.R., Shu V., Zwingelstein C., Tobias J., Poole L., Stolzenbach J.C., Creasey A.A. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA 2003, 290:238-247.
2. Alavi S.M., Sharifi M., Eghtesad M. Bacterial sepsis: challenges of diagnosis and treatment in a teaching hospital southwest of Iran. Jundishapur J. Microbiol. 2014, 7:e9082.
3. Bernard G.R., Vincent J.L., Laterre P.F., LaRosa S.P., Dhainaut J.F., Lopez-Rodriguez A., Steingrub J.S., Garber G.E., Helterbrand J.D., Ely E.W., Fisher C.J. Efficacy and safety of recombinant human activated protein C for severe sepsis. N. Engl. J. Med. 2001, 344:699-709.
4. Brun-Buisson C. The epidemiology of the systemic inflammatory response. Intensive Care Med. 2000, 26(Suppl. 1):S64-S74.
5. Corrigan J.J., Ray W.L., May N. Changes in the blood coagulation system associated with septicemia. N. Engl. J. Med. 1968, 279:851-856.
6. de Jong H.K., van der Poll T., Wiersinga W.J. The systemic pro-inflammatory response in sepsis. J. Innate Immun. 2010, 2:422-430.
7. Desai S., Jones S.L., Turner K.L., Hall J., Moore L.J. Nucleated red blood cells are associated with a higher mortality rate in patients with surgical sepsis. Surg. Infect. (Larchmt) 2012, 13:360-365.
8. Finigan J.H. The coagulation system and pulmonary endothelial function in acute lung injury. Microvasc. Res. 2009, 77:35-38.
9. Horeczko T., Green J.P., Panacek E.A. Epidemiology of the systemic inflammatory response syndrome (SIRS) in the emergency department. West. J. Emerg. Med. 2014, 15:329-336.
10. Lever A., Mackenzie I. Sepsis: definition, epidemiology, and diagnosis. BMJ 2007, 335:879-883.
11. Li X., Zheng Z., Ma X. Unfractionated heparin inhibits lipopolysaccharide-induced inflammatory response through blocking p38 MAPK and NF-kappaB activation on endothelial cell. Cytokine 2012, 60:114-121.
12. Li N., Hu X., Liu Y., Wang Y., Liu J., Cai W., Bai X., Zhu X., Han J., Hu D. Systemic inflammatory responses and multiple organ dysfunction syndrome following skin burn wound and Pseudomonas aeruginosa infection in mice. Shock 2013, 40:152-159.
13. Liu X.L., Wang X.Z., Liu X.X., Hao D., Jaladat Y., Lu F., Sun T., Lv C.J. Low-dose heparin as treatment for early disseminated intravascular coagulation during sepsis: a prospective clinical study. Exp. Ther. Med. 2014, 7:604-608.
14. Marti-Carvajal A.J., Sola I., Gluud C., Lathyris D., Cardona A.F. Human recombinant protein C for severe sepsis and septic shock in adult and paediatric patients. Cochrane Database Syst. Rev. 2012, 12:CD004388.
15. McClelland H., Moxon A. Early identification and treatment of sepsis. Nurs. Times 2014, 110:14-17.
16. Nasiripour S., Gholami K., Mousavi S., Mohagheghi A., Radfar M., Abdollahi M., Khazaeipour Z., Mojtahedzadeh M. Comparison of the effects of enoxaparin and heparin on inflammatory biomarkers in patients with ST-segment elevated myocardial infarction: a prospective open label pilot clinical trial. Iran. J. Pharm. Res. 2014, 13:583-590.
17. Nelson R.M., Cecconi O., Roberts W.G., Aruffo A., Linhardt R.J., Bevilacqua M.P. Heparin oligosaccharides bind L- and P-selectin and inhibit acute inflammation. Blood 1993, 82:3253-3258.
18. Page C. Heparin and related drugs: beyond anticoagulant activity. ISRN Pharmacol. 2013, 2013:910743.
19. Ritter C., Andrades M., Frota Junior M.L., Bonatto F., Pinho R.A., Polydoro M., Klamt F., Pinheiro C.T., Menna-Barreto S.S., Moreira J.C., Dal-Pizzol F. Oxidative parameters and mortality in sepsis induced by cecal ligation and perforation. Intensive Care Med. 2003, 29:1782-1789.
20. Sener G., Toklu H., Ercan F., Erkanli G. Protective effect of beta-glucan against oxidative organ injury in a rat model of sepsis. Int. Immunopharmacol. 2005, 5:1387-1396.
21. Tian L., Catt J.W., O'Neill C., King N.J. Expression of immunoglobulin superfamily cell adhesion molecules on murine embryonic stem cells. Biol. Reprod. 1997, 57:561-568.
22. Vincent J.L. Acute kidney injury, acute lung injury and septic shock: how does mortality compare?. Contrib. Nephrol. 2011, 174:71-77.
23. von Dadelszen P., Magee L.A., Marshall J.C., Rotstein O.D. The maternal syndrome of preeclampsia: a forme fruste of the systemic inflammatory response syndrome. Sepsis 2000, 4:43-47.
24. Wygrecka M., Jablonska E., Guenther A., Preissner K.T., Markart P. Current view on alveolar coagulation and fibrinolysis in acute inflammatory and chronic interstitial lung diseases. Thromb. Haemost. 2008, 99:494-501.
25. Young E. The anti-inflammatory effects of heparin and related compounds. Thromb. Res. 2008, 122:743-752.